Approval · Notice of Compliance 22931 · 2019
ACT CABERGOLINE: Notice of Compliance 22931
Issued November 22, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22931
- Date
- November 22, 2019
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Merger - buyout
- Canadian reference product
- DOSTINEX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT CABERGOLINE | 02301407 | Dormant |
Medicinal ingredients
- CABERGOLINE 0.5 MG per TAB